Effectiveness of edaravone in preventing contrast-induced nephropathy in high-risk patients undergoing coronary angiography: A randomized, double-blind trial.
Azam EsmailnejadSepideh Zununi VahedSeyyedeh Mina HejazianNaser AslanabadiHassanali Lotfollahhi GharakhanluMajid SaraeiAhmad AhmadzadehpournakyKasra ArdalanMohammad Reza ArdalanSamad Ghaffari BavilPublished in: Pharmacology research & perspectives (2024)
Contrast-induced nephropathy (CIN) is a serious complication that occurs subsequent to the administration of contrast media for therapeutic angiographic interventions. As of present, no effective therapy exists to prevent its occurrence. This single-center double-blind randomized controlled trial aimed to evaluate the effect of edaravone, an antioxidant, in a group of high-risk patients undergoing coronary angiography. Ninety eligible patients with chronic kidney disease Stages 3-4 were randomly assigned to either the control group (n = 45) or the intervention group (n = 45). In the intervention group, one dosage of edaravone (60 mg) in 1 L of normal saline was infused via a peripheral vein 1 h prior to femoral artery-directed coronary angiography. Patients in the control group received an equal amount of infusion in their last hour before angiography. Both groups received intravenous hydration with 0.9% sodium 1 mL/kg/h starting 12 h before and continuing for 24 h after angiography. The primary outcome measure was the onset of CIN, defined as a 25% increase in serum creatinine levels 120 h after administration of contrast media. The occurrence of CIN was observed in 5.5% (n = 5) of the studied population: 2.2% of patients in the intervention group (n = 1) and 8.9% of controls (n = 4). However, this difference was not statistically significant. Administration of a single dosage of edaravone 1 h prior to infusion of contrast media led to a reduction in the incidence of CIN. Further investigations, employing larger sample sizes, are warranted to gain a comprehensive understanding of its efficacy.
Keyphrases
- randomized controlled trial
- patients undergoing
- magnetic resonance
- study protocol
- end stage renal disease
- clinical trial
- chronic kidney disease
- ejection fraction
- computed tomography
- risk assessment
- double blind
- low dose
- blood pressure
- optical coherence tomography
- prognostic factors
- peritoneal dialysis
- systematic review
- stem cells
- high dose
- placebo controlled
- patient reported outcomes
- oxidative stress
- physical activity
- phase ii
- high glucose
- drug induced
- bone marrow
- anti inflammatory
- medical education